Frequency Therapeutics Stock News

Here's what you need to know about trading penny stocks today The post What to Know About Buying Penny Stocks on May 10th appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStoc

LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate regenera

Why these penny stocks could be worth watching as April ends The post Best Penny Stocks to Buy in 2022? 3 to Watch in Late April appeared first on Penny Stocks to Buy, Picks, News and Information | Pe

Why these penny stocks could be worth watching as April ends The post Best Penny Stocks to Buy in 2022? 3 to Watch in Late April appeared first on Penny Stocks to Buy, Picks, News and Information | Pe

Frequency Therapeutics press release (FREQ): Q4 GAAP EPS of -$0.62 misses by $0.98.“The year ahead has numerous milestones for Frequency and our lead program FX-322, as we plan…

Tarrytown, New York, March 11, 2022 (GLOBE NEWSWIRE) -- ENT and Allergy Associates, LLP (ENTA), the largest ear, nose, throat, allergy, and audiology practice in the nation, which continuously strives to encourage and promote the very best medical advancements in the fields of otolaryngology, immunology, and audiology announced today that it is currently participating in a nationwide clinical trial of a novel regenerative medicine designed to restore hearing in patients with acquired sensorineural hearing loss (SNHL). Led by ENTA''s fellowship-trained otologist/neurotologist Sujana Chandrasekhar, MD, FACS, its New York City office currently is enrolling subjects in a study of the drug candidate FX-322, being developed by Frequency Therapeutics. Frequency Therapeutics, Inc. is a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person''s innate regenerative potential to restore function. FX-322 is designed to regenerate cells in the ear lost to acquired SNHL and, to date, has shown hearing improvements in key measures of hearing function in three separate studies in which a single dose of FX-322 was administered.

Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of 105.88% and 31.53%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for th

LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate regenera

Frequency Therapeutics Inc (NASDAQ: FREQ) shared the results from its FX-322-113 study of FX-322 in severe sensorineural hearing loss (SNHL). The Phase 1b study, FX-322, was associated with a heari

(RTTNews) - Frequency Therapeutics, Inc. (FREQ) reported the results from its FX-322-113 study, a placebo-controlled trial evaluating the administration of FX-322 in subjects with severe sensorineural hearing loss. In the study, FX-322 was associated with a hearing signal as shown by improvements by four subjects in a sentence-in-noise test.

Millennium Management LLC increased its stake in shares of Frequency Therapeutics, Inc. (NASDAQ:FREQ) by 2,460.4% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 188,802 shares of the companys stock after buying an additional 181,428 shares during the quarter. Millennium Management []

UBS Asset Management Americas Inc. grew its position in Frequency Therapeutics, Inc. (NASDAQ:FREQ) by 151.5% during the 2nd quarter, HoldingsChannel reports. The fund owned 40,496 shares of the companys stock after purchasing an additional 24,396 shares during the period. UBS Asset Management Americas Inc.s holdings in Frequency Therapeutics were worth $403,000 at the end of []

State Street Corp lowered its stake in shares of Frequency Therapeutics, Inc. (NASDAQ:FREQ) by 56.0% in the second quarter, according to its most recent 13F filing with the SEC. The fund owned 610,346 shares of the companys stock after selling 775,926 shares during the period. State Street Corps holdings in Frequency Therapeutics were worth $6,079,000 []

Shares of Frequency Therapeutics, Inc. (NASDAQ:FREQ) have earned an average rating of Buy from the six ratings firms that are presently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average twelve-month target price among analysts that []

Frequency Therapeutics (NASDAQ:FREQ) posted its earnings results on Monday. The company reported ($0.73) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.57) by ($0.16), Fidelity Earnings reports. Frequency Therapeutics had a negative return on equity of 29.15% and a negative net margin of 152.00%. NASDAQ:FREQ opened at $6.37 on Wednesday. The company []